Research ArticleOriginal Article

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer

Runsen Jin, Chengming Liu, Sufei Zheng, Xinfeng Wang, Xiaoli Feng, Hecheng Li, Nan Sun and Jie He
Cancer Biology & Medicine August 2020, 17 (3) 768-781; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0121

References

  1. 1.↵
    2. Torre LA,
    3. Bray F,
    4. Siegel RL,
    5. Ferlay J,
    6. Lortet-Tieulent J,
    7. Jemal A.
    Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87–108.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Chen W,
    3. Zheng R,
    4. Baade PD,
    5. Zhang S,
    6. Zeng H,
    7. Bray F, et al.
    Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115–32.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Wakelee H,
    3. Belani CP.
    Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist. 2005; 10 Suppl 3: 1–10.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    2. Gainor JF,
    3. Shaw AT.
    Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013; 31: 3987–96.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Lee CK,
    3. Man J,
    4. Lord S,
    5. Cooper W,
    6. Links M,
    7. Gebski V, et al.
    Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018; 4: 210–6.
    OpenUrl
  6. 6.↵
    2. Ribas A,
    3. Wolchok JD.
    Cancer immunotherapy using checkpoint blockade. Science. 2018; 359: 1350–5.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    2. Herbst RS,
    3. Baas P,
    4. Kim DW,
    5. Felip E,
    6. Perez-Gracia JL,
    7. Han JY, et al.
    Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387: 1540–50.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Rittmeyer A,
    3. Barlesi F,
    4. Waterkamp D,
    5. Park K,
    6. Ciardiello F,
    7. von Pawel J, et al.
    Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389: 255–65.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Borghaei H,
    3. Paz-Ares L,
    4. Horn L,
    5. Spigel DR,
    6. Steins M,
    7. Ready NE, et al.
    Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015; 373: 1627–39.
    OpenUrlCrossRefPubMed
  10. 10.
    2. Brahmer J,
    3. Reckamp KL,
    4. Baas P,
    5. Crino L,
    6. Eberhardt WE,
    7. Poddubskaya E, et al.
    Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373: 123–35.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Wu YL,
    3. Lu S,
    4. Cheng Y,
    5. Zhou C,
    6. Wang J,
    7. Mok T, et al.
    Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: checkmate 078 randomized phase III clinical trial. J Thorac Oncol. 2019; 14: 867–75.
    OpenUrlPubMed
  12. 12.↵
    2. Brustugun OT,
    3. Sprauten M,
    4. Helland A.
    Real-world data on nivolumab treatment of non-small cell lung cancer. Acta Oncol. 2017; 56: 438–40.
    OpenUrl
  13. 13.
    2. Dudnik E,
    3. Moskovitz M,
    4. Daher S,
    5. Shamai S,
    6. Hanovich E,
    7. Grubstein A, et al.
    Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Lung Cancer. 2018; 126: 217–23.
    OpenUrlPubMed
  14. 14.↵
    2. Ahn BC,
    3. Pyo KH,
    4. Xin CF,
    5. Jung D,
    6. Shim HS,
    7. Lee CY, et al.
    Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019; 145: 1613–23.
    OpenUrl
  15. 15.↵
    2. Yoneda K,
    3. Imanishi N,
    4. Ichiki Y,
    5. Tanaka F.
    Immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). J UOEH. 2018; 40: 173–89.
    OpenUrl
  16. 16.↵
    2. Gainor JF,
    3. Shaw AT,
    4. Sequist LV,
    5. Fu X,
    6. Azzoli CG,
    7. Piotrowska Z, et al.
    EGFR Mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016; 22: 4585–93.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Fehrenbacher L,
    3. Spira A,
    4. Ballinger M,
    5. Kowanetz M,
    6. Vansteenkiste J,
    7. Mazieres J, et al.
    Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387: 1837–46.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Schlam I,
    3. Dyehouse KM,
    4. Ward PJ.
    Application of NCCN guidelines in PD-L1 expression for patients with stage IV non-small cell lung cancer. J Clin Oncol. 2018; 36: e15030.
  19. 19.↵
    2. Zhou W,
    3. Christiani DC.
    East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011; 30: 287–92.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Dearden S,
    3. Stevens J,
    4. Wu YL,
    5. Blowers D.
    Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24: 2371–6.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Chen J,
    3. Yang H,
    4. Teo ASM,
    5. Amer LB,
    6. Sherbaf FG,
    7. Tan CQ, et al.
    Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020; 52: 177–86.
    OpenUrlCrossRef
  22. 22.↵
    2. Osta BEE,
    3. Behera M,
    4. Kim S,
    5. Berry LD,
    6. Sica G,
    7. Pillai RN, et al.
    Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: lung cancer mutation consortium (LCMC) database. J Clin Oncol. 2017; 35: 9021.
    OpenUrl
  23. 23.↵
    2. Jordan EJ,
    3. Kim HR,
    4. Arcila ME,
    5. Barron D,
    6. Chakravarty D,
    7. Gao J, et al.
    Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017; 7: 596–609.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    2. Charoentong P,
    3. Finotello F,
    4. Angelova M,
    5. Mayer C,
    6. Efremova M,
    7. Rieder D, et al.
    Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017; 18: 248–62.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Akbay EA,
    3. Koyama S,
    4. Carretero J,
    5. Altabef A,
    6. Tchaicha JH,
    7. Christensen CL, et al.
    Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discovery. 2013; 3: 1355–63.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    2. Coelho MA,
    3. de Carne Trecesson S,
    4. Rana S,
    5. Zecchin D,
    6. Moore C,
    7. Molina-Arcas M, et al.
    Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017; 47: 1083–99.e6.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Ribas A,
    3. Hu-Lieskovan S.
    What does PD-L1 positive or negative mean? J Exp Med. 2016; 213: 2835–40.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    2. Teng MW,
    3. Ngiow SF,
    4. Ribas A,
    5. Smyth MJ.
    Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015; 75: 2139–45.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    2. Zhang Y,
    3. Ma Y,
    4. Li Y,
    5. Shen X,
    6. Yu Y,
    7. Pan Y, et al.
    Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations. J Cancer Res Clin Oncol. 2019; 145: 747–57.
    OpenUrl
  30. 30.↵
    2. Rizvi H,
    3. Sanchez-Vega F,
    4. La K,
    5. Chatila W,
    6. Jonsson P,
    7. Halpenny D, et al.
    Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018; 36: 633–41.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Jiang P,
    3. Gu S,
    4. Pan D,
    5. Fu J,
    6. Sahu A,
    7. Hu X, et al.
    Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24: 1550–8.
    OpenUrlPubMed
  32. 32.↵
    2. Liu C,
    3. Zheng S,
    4. Jin R,
    5. Wang X,
    6. Wang F,
    7. Zang R, et al.
    The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2020; 470: 95–105.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Higgins JP,
    3. Altman DG,
    4. Gotzsche PC,
    5. Juni P,
    6. Moher D,
    7. Oxman AD, et al.
    The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.
    OpenUrlFREE Full Text
  34. 34.↵
    2. Dong ZY,
    3. Zhang JT,
    4. Liu SY,
    5. Su J,
    6. Zhang C,
    7. Xie Z, et al.
    EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology. 2017; 6: e1356145.
  35. 35.↵
    2. Garassino MC,
    3. Cho BC,
    4. Kim JH,
    5. Mazieres J,
    6. Vansteenkiste J,
    7. Lena H, et al.
    Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018; 19: 521–36.
    OpenUrlPubMed
  36. 36.↵
    2. Reck M,
    3. Mok TSK,
    4. Nishio M,
    5. Jotte RM,
    6. Cappuzzo F,
    7. Orlandi F, et al.
    Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019; 7: 387–401.
    OpenUrl
  37. 37.↵
    2. Seo JS,
    3. Ju YS,
    4. Lee WC,
    5. Shin JY,
    6. Lee JK,
    7. Bleazard T, et al.
    The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012; 22: 2109–19.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Yang H,
    3. Shi J,
    4. Lin D,
    5. Li X,
    6. Zhao C,
    7. Wang Q, et al.
    Prognostic value of PD-L1 expression in combination with CD8(+) TILs density in patients with surgically resected non-small cell lung cancer. Cancer Med. 2018; 7: 32–45.
    OpenUrl
  39. 39.↵
    2. Su S,
    3. Dong ZY,
    4. Xie Z,
    5. Yan LX,
    6. Li YF,
    7. Su J, et al.
    Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. J Thorac Oncol. 2018; 13: 1688–75.
    OpenUrl
  40. 40.↵
    2. Hsu KH,
    3. Huang YH,
    4. Tseng JS,
    5. Chen KC,
    6. Ku WH,
    7. Su KY, et al.
    High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naive advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer. 2019; 127: 37–43.
    OpenUrl
  41. 41.↵
    2. Mazieres J,
    3. Drilon A,
    4. Lusque A,
    5. Mhanna L,
    6. Cortot AB,
    7. Mezquita L, et al.
    Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30: 1321–8.
    OpenUrlPubMed
  42. 42.↵
    2. Ji M,
    3. Liu Y,
    4. Li Q,
    5. Li X,
    6. Ning Z,
    7. Zhao W, et al.
    PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biol Ther. 2016; 17: 407–13.
    OpenUrl
  43. 43.↵
    2. Toki MI,
    3. Mani N,
    4. Smithy JW,
    5. Liu Y,
    6. Altan M,
    7. Wasserman B, et al.
    Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations. J Thorac Oncol. 2018; 13: 1884–96.
    OpenUrl
  44. 44.↵
    2. Ng TL,
    3. Liu Y,
    4. Dimou A,
    5. Patil T,
    6. Aisner DL,
    7. Dong Z, et al.
    Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer. 2019; 125: 1038–49.
    OpenUrl
  45. 45.↵
    2. Wang GZ,
    3. Zhang L,
    4. Zhao XC,
    5. Gao SH,
    6. Qu LW,
    7. Yu H, et al.
    The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat Commun. 2019; 10: 1125.
    OpenUrl
  46. 46.↵
    2. Hastings K,
    3. Yu H,
    4. Wei W,
    5. Sanchez-Vega F,
    6. DeVeaux M,
    7. Choi J, et al.
    EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Ann Oncol. 2019; 30: 1311–20.
    OpenUrlCrossRefPubMed
  47. 47.↵
    2. Zhang Y,
    3. Sheng J,
    4. Kang S,
    5. Fang W,
    6. Yan Y,
    7. Hu Z, et al.
    Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One. 2014; 9: e107161.
  48. 48.↵
    2. Riely GJ,
    3. Pao W,
    4. Pham D,
    5. Li AR,
    6. Rizvi N,
    7. Venkatraman ES, et al.
    Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12: 839–44.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords